Crown Bioscience

In this on-demand webinar, Rekha Pal, PhD, provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success. Watch now: hubs.la/Q04hsGqq0

This study highlights how advanced organoid-based 3D in vitro platforms can improve the translational relevance of immunotherapy testing by more accurately modeling the tumor microenvironment. hubs.la/Q04h4dQD0

Did you know skin cancer is the most common type of cancer in the US? ¹ This Skin Cancer Awareness Month, we’re highlighting research advancements in melanoma cancer treatment. cancer.gov/types/skin ¹hubs.la/Q04h49LW0

From target validation and biomarker discovery to hypothesis testing and AI/ML model development, Crown Bioscience Data Licensing empowers confident decision-making during oncology drug discovery. Discover more: hubs.la/Q04gyhBn0

Crown Bioscience’s Model of the Month, CR9831, is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC (ABBV-400). Partner with us to access models that mirror today’s clinical landscape. hubs.la/Q04grlfJ0

Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy. hubs.la/Q04g2ZRL0

Join Crown Bioscience & Vilber for “Advancing Oncology Drug Development: From Resistance Mechanisms to Preclinical Innovation,” an afternoon of scientific discussion focused on overcoming resistance and accelerating oncology drug development. Register now: hubs.la/Q04g5Zlg0

Crown Bioscience CEO John Gu talks about the need for different approaches among different cultures – with firsthand insights into how we achieve success across our multicultural teams. Read the interview in full: hubs.la/Q04fpqst0

This World Ovarian Cancer Day, we’re highlighting the need to overcome resistance to existing treatments. Precision medicine & targeted therapies like PARPi¹ help improve patient outcomes but resistance to PARPi remains a challenge.hubs.la/Q04fp09s0 ¹hubs.la/Q04fnZ4Z0

AACR may be over, but the science continues. We’re sharing a closer look at four of our poster presentations, highlighting how we’re advancing translational research across some of today’s most complex therapeutic challenges. hubs.la/Q04fnYwg0

Listen in to our latest Smart Biotech Scientist Podcast episode, as Dr. David Brühlmann speaks with Bryan Miller about the importance of developing a robust strategy and why partnering with a CRO provides value. Catch their insights in full: hubs.la/Q04fpc1q0

Advanced preclinical systems are helping researchers model complex CGT mechanisms with greater accuracy. Benjamin Wilkin explains why this will be essential for translating promising therapies into clinical success as the field continues to advance: hubs.la/Q04fph1S0

We’re excited to share that the human biospecimen and biomarker services business of Crown Bioscience Germany GmbH now has a dedicated website. Visit us at hubs.la/Q04fcgWB0

Our Associate Director Hester Bange will be heading to Sweden for ‘Advances in Cell-Based Screening in Drug Discovery 2026’. If you’re attending the conference, don’t miss this chance to meet with our oncology expert! Schedule a meeting: hubs.la/Q04d-Gg70

If your biomarker data doesn’t deliver clarity with confidence, it’s not working hard enough. With a focus on precision, reproducibility, and scientific rigor, we make sure your biomarker strategy is built on data you can trust. hubs.la/Q04dHfrH0

Meet us at #SwissBiotechDay in Basel from May 4-5, Booth 8, Foyer 2. Discover how we can partner with you to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Schedule a meeting with us: hubs.la/Q04dS8gt0

Looking for the best customer experience available in the industry? Explore our monthly Customer Satisfaction Report: hubs.la/Q04dGLSZ0

🎙️In this Smart Biotech Scientist Podcast episode, Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, explains the strengths of our partnership with Medicines Discovery Catapult to deliver this. Tune in now: hubs.la/Q04dbzF60

Hear from Luke Yu about why our diverse cultures and global presence are his favorite things about working at Crown Bioscience. We understand our responsibility to our customers and our people extends to the societies and communities we all share.

In this insight-packed piece, Crown CEO John Gu talks about his unique approach to leadership, and why hearing the opposite side of a proposal is critical in today's environment. Dive into the full interview: hubs.la/Q04dbj9C0